WRLD A.LIVE

19:001 report

• How Trump Destroyed South Africa’s Effort to Slow HIV Transmission The Intercept

18:00nothing heard

17:00nothing heard

16:00nothing heard

15:00nothing heard

14:00nothing heard

13:00nothing heard

12:00nothing heard

11:00nothing heard

10:00nothing heard

09:00nothing heard

08:001 report

• IDWeek 2026: ISL/LEN on track to become the first once-weekly oral HIV therapy Pharmaceutical Technology

23:002 reports

• UNAIDS congratulates Barbados on eliminating vertical transmission of HIV UNAIDS
• Barbados eliminates mother-to-child transmission of HIV Pan American Health Organization (PAHO)

22:002 reports

• Doxycycline PEP linked to sharp drops in syphilis and chlamydia across Australia Bioengineer.org
• Modelling shows doxyPEP could account for 1.9% of doxycycline use in Europe Aidsmap

21:00nothing heard

20:00nothing heard

19:001 report

• Single-domain antibody-conjugated lipid nanoparticles for selective mRNA delivery to CD4⁺ T cells and Brec1-mediated excision of HIV-1 proviral DNA Nature

18:001 report

• Long-Acting Cabenuva Durably Suppresses HIV in Real-World Study POZ

17:00nothing heard

16:00nothing heard

15:00nothing heard

14:00nothing heard

13:00nothing heard

12:001 report

• A Markov transition analysis to study changes in HIV prevention strategies among men who have sex with men in the French ANRS-PREVENIR cohort Nature

11:00nothing heard

10:00nothing heard

09:00nothing heard

08:002 reports

• New Data Link Cabotegravir PrEP to Few HIV Cases, Higher Adherence The American Journal of Managed Care
• [IDWeek 2026] Infectious Disease Advisor | Long-acting cabotegravir linked to low rates of HIV-1 detection European AIDS Treatment Group

07:00nothing heard

06:00nothing heard

05:00nothing heard

04:00nothing heard

03:00nothing heard

02:00nothing heard

01:00nothing heard

00:001 report

• PH, Australia eye joint purchase of HIV drugs The Manila Times

08:001 report

• Gaps Persist Across the HIV Care Cascade in Youth DocWireNews

22:002 reports

• Six injections a year instead of 365 pills: Can long-acting HIV treatment change care in Africa? The London School of Hygiene & Tropical Medicine
• UNAIDS Board rejects plans to shut down the agency, backs transformation Citizen Digital

21:002 reports

• Five years of U.S. real-world evidence reinforce the durable effectiveness and long-term persistence of ViiV Healthcare’s Cabenuva The Joplin Globe
• Long-Acting ART Shot Works Well for Adherence Issues Medscape

20:00nothing heard

19:001 report

• HIV treatment emergency preparedness requires greater pharmacy involvement, experts argue Hospital Pharmacy Europe

18:001 report

• Safer Solutions: The Urgent Connection Between Smoking and HIV R Street Institute

17:001 report

• Study Details Surprising Human Immune Cell Link to HIV POZ

16:00nothing heard

15:00nothing heard

14:00nothing heard

13:00nothing heard

12:00nothing heard

11:00nothing heard

10:00nothing heard

09:002 reports

• AHF calls for responsible, stigma-free HIV reporting Inquirer.net
• Expert calls for stronger HIV prevention programs for Filipino youth Philippine News Agency

08:00nothing heard

07:00nothing heard

06:001 report

• [Press release] UNAIDS board rejects sunsetting of UNAIDS European AIDS Treatment Group

05:00nothing heard

04:002 reports

• IDSA: Cabotegravir + rilpivirine long-acting antiretroviral therapy beneficial in HIV Medical Xpress
• Updated HIV treatment guidelines address payer barriers and add Bixlenvo Managed Healthcare Executive

03:00nothing heard

02:005 reports

• UNAIDS has a survival plan. But will it work? Devex
• UNAIDS board rejects plan to shut down HIV/AIDS programme People Daily
• One year after USAID funding cuts, another aid agency catering to Africa’s health sector narrowly escapes folding amid global funding crisis Business Insider Africa
• UNAIDS board rejects sunsetting of UNAIDS UNAIDS
• UNAIDS Board Rejects ‘Sunsetting’, Opting Instead For Transformation Health Policy Watch

11:001 report

• EXPLAINER: What is Human Immunodeficiency Virus or HIV? GMA Network

10:001 report

• One Dose of Experimental Antibody Kept HIV-Like Virus in Remission For 4 Years in a Monkey ScienceAlert

09:00nothing heard

08:00nothing heard

07:00nothing heard

06:00nothing heard

05:00nothing heard

04:00nothing heard

03:005 reports

• Five years of U.S. real-world evidence reinforce the durable effectiveness and long-term persistence of ViiV Healthcare’s Cabenuva Yahoo Finance
• Long-Acting HIV Regimen Maintains High Viral Suppression in Real-World Study Infectious Disease Special Edition
• Jean Van Wyk, MBChB, MFPM, on New Cabotegravir Data at IDWeek 2026 Infectious Disease Special Edition
• EXPLAINER: What is Human Immunodeficiency Virus or HIV? GMA Network
• Media urged to curb HIV stigma through responsible reporting BusinessWorld Online

02:00nothing heard

01:00nothing heard

00:001 report

• Abrenian doctor presents advanced HIV case at international medical conference in Washington Daily Tribune Abra

22:001 report

• HIV prevention gaps leave young Filipinos at risk BusinessWorld Online

21:00nothing heard

20:001 report

• Young Abra doctor presents paper on HIV at prestigious infectious disease conference in US Rappler Abra

06:002 reports

• UNC School of Medicine Researchers Identify New Pathway That Helps HIV Hide in the Body Despite Treatment UNC Health
• UNC School of Medicine | Researchers identify new pathway that helps HIV hide in the body despite treatment European AIDS Treatment Group

05:00nothing heard

04:00nothing heard

03:005 reports

• [IDWeek 2026] Contagion Live | Asuptegravir lowers HIV-1 RNA up to 2.36 logs in early monotherapy European AIDS Treatment Group
• Once-Weekly Oral HIV Regimen Matches Daily Therapy in Phase 3 Trials Infectious Disease Special Edition
• Novel Doravirine/Islatravir Yields Similar Patient-Reported Outcomes in HIV-1 Infectious Disease Advisor
• [IDWeek 2026] Infectious Disease Advisor | Novel doravirine/islatravir yields similar patient-reported outcomes in HIV-1 European AIDS Treatment Group
• [IDWeek 2026] Infectious Disease Advisor | Recombinant zoster vaccination reduces cardiovascular risks in HIV European AIDS Treatment Group

02:00nothing heard

01:002 reports

• DZIF | HIV’s genetic remnants are not as silent as they seem European AIDS Treatment Group
• Newly identified protein pathway helps HIV stay hidden despite treatment Phys.org

00:001 report

• Accurate HIV reporting sought The Manila Times Metro Manila

01:003 reports

• TheBodyPro | Study findings make a case for an unusual long-acting ART pairing: cabotegravir plus lenacapavir European AIDS Treatment Group
• Oral ART or Long-Acting Injectables for HIV: Which Is Right for You? Everyday Health
• Long-acting injected combo drug keeps HIV in check, real-world study finds CIDRAP

23:001 report

• Using AI in the global fight against HIV Medical Xpress

22:00nothing heard

21:00nothing heard

20:00nothing heard

19:00nothing heard

18:00nothing heard

17:00nothing heard

16:00nothing heard

15:00nothing heard

14:00nothing heard

13:00nothing heard

12:00nothing heard

11:00nothing heard

10:00nothing heard

09:00nothing heard

08:001 report

• Palawan summit calls for stronger action against HIV stigma The Manila Times Palawan

07:00nothing heard

06:00nothing heard

05:001 report

• Clinical trial establishes effective HIV dosing regimen for full-term newborns News-Medical

04:004 reports

• International study helps support FDA approval of HIV drug for newborns Medical Xpress
• Simpler, Long-Acting Antiretroviral Strategies Reshape HIV Prevention and Care Bioengineer.org
• Oral ART or Long-Acting Injectables for HIV: Which Is Right for You? Yahoo Health
• Study: Most who switch to long-acting HIV therapy stick with it Healio

20:001 report

• TaiMed Biologics Reports IDWeek 2026 Data Highlighting TMB-365 and Its Potential Across Long-Acting HIV Combinations The Manila Times

19:00nothing heard

18:001 report

• An Update on HIV/AIDS in North Macedonia The Borgen Project

17:00nothing heard

16:00nothing heard

15:00nothing heard

14:00nothing heard

13:00nothing heard

12:00nothing heard

11:00nothing heard

10:006 reports

• Five years of U.S. real-world evidence reinforce the durable effectiveness and long-term persistence of ViiV Healthcare’s Cabenuva BioSpace
• UCT advances injectable HIV treatment and prevention UCT News
• Real-World HIV Study Allays Doubts About Long-Acting ART Injectables MedPage Today
• Five years of U.S. real-world evidence reinforce the durable effectiveness and long-term persistence of ViiV Healthcare’s Cabenuva Business Wire
• Broadly neutralising antibody plus cabotegravir maintains viral suppression for at least a year Aidsmap
• Long-Acting HIV Treatment Maintains 94% Viral Suppression: IDWeek 2026 European Medical Journal

09:00nothing heard

08:002 reports

• Bioengineer.org | Model projects 77% fewer HIV infections with UNAIDS 2030 targets European AIDS Treatment Group
• [Call to action] AVAC | No time to lose: Reaching at least three million with LEN for PrEP by 2027 European AIDS Treatment Group

07:00nothing heard

06:00nothing heard

05:00nothing heard

04:00nothing heard

03:00nothing heard

02:001 report

• T cell survival protein controls gene activity, offering clues to HIV persistence Medical Xpress

01:00nothing heard

00:001 report

• HIV genetic remnants can alter immune cells in ways that may promote viral persistence Medical Xpress

16:001 report

• HIV Finds Escape Routes From Preventive Antibody – But Newer Antibodies May Close Them POZ

15:00nothing heard

14:00nothing heard

13:00nothing heard

12:00nothing heard

11:00nothing heard

10:00nothing heard

09:00nothing heard

08:00nothing heard

07:002 reports

• Infectious Disease Advisor | Long-term ART does not reduce anogenital cancer risk in people with HIV European AIDS Treatment Group
• Bioengineer.org | HIV self-testing: A decade of delay leaves millions unaware of their status European AIDS Treatment Group

06:00nothing heard

05:001 report

• AHF, GNP+ Webinar Puts Spotlight on Global HIV/AIDS Response Yahoo Finance

04:001 report

• Contagion Live | HHS updates guidelines for antiretroviral treatment of HIV European AIDS Treatment Group

03:002 reports

• Historic Funding Drop Threatens Global HIV Progress Infectious Disease Special Edition
• UNAIDS | World AIDS Day 2026: Ending AIDS starts with access European AIDS Treatment Group